drugset / Trial / NCT06834399
TATE and KN046 in MCRC
Phase 2
Terminated
42 enrolled
Zhejiang Raygene Pharmaceuticals Co., Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc fusion protein injection) in patients with liver metastases from colorectal cancer.
Timeline
- Start
- 2023-04-27
- Primary completion
- 2024-12-17
- Completion
- 2025-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ERFONRILIMAB | Monoclonal antibody | 5 mg/kg | — |